Metastatic adeoid cystic carcinoma of the salivary gland

a 2015

Metastatic adeoid cystic carcinoma of the salivary gland

BRANČÍKOVÁ, Dagmar, Markéta PROTIVÁNKOVÁ, Lenka OSTŘÍŽKOVÁ, Zdeněk MECHL, Radek PEJCOCH et. al.

Basic information

Original name

Metastatic adeoid cystic carcinoma of the salivary gland

Name in Czech

Adenoidně cystický nádor slinných žláz

Authors

BRANČÍKOVÁ, Dagmar (203 Czech Republic, guarantor, belonging to the institution), Markéta PROTIVÁNKOVÁ (203 Czech Republic, belonging to the institution), Lenka OSTŘÍŽKOVÁ (203 Czech Republic, belonging to the institution), Zdeněk MECHL (203 Czech Republic, belonging to the institution) and Radek PEJCOCH (203 Czech Republic)

Edition

2015 ASCO Annual Meeting, 2015

Other information

Language

English

Type of outcome

Konferenční abstrakt

Field of Study

30200 3.2 Clinical medicine

Country of publisher

United States of America

Confidentiality degree

není předmětem státního či obchodního tajemství

Impact factor

Impact factor: 20.982

RIV identification code

RIV/00216224:14110/15:00083406

Organization unit

Faculty of Medicine

ISSN

Keywords in English

Adeoid cystic carcinomas

Abstract

V originále

Background: Adeoid cystic carcinomas of the salivary gland account for approximately 10% of parotid gland tumors. Well-differentiated tumors are characterized by a slow growth rate, a low recurrence rate after complete surgical excision and rare metastatic potential. High-grade tumors are more aggressive, local reccurence rate after surgery approaches 60% and 30% develop distant metastases. We are presenting small group - 6 cases with longer survival after targeted, biological therapy Methods: 6 patients ( 4 males and 2 female) with median age: 50 years. Multiple lung and liver dissemination with all of them. Histology: adenoid cystic carcinoma, KRAS wt, ckit wt, BRAF wt with all. In one women PDGFR mutation on exon 10. No comorbidities, all tumors was clinically symptomatic. Treatment: Combination Cisplatin 50mg/m2 day 1 +Fluorouracil 100mg/m2 48 h continual and docetaxel 60mg/m2 day 1 was used on the first line , after progression in the second line patient was treated with Mitoxantron monotherapy . Third line we indicated imatinib mesylate to patients ckit wt and sunitinib undervent female patient with PDGFR mutation. Results: Therapy using docetaxel and platinum and fluorouracil was effective ( PR 4 patient , median TTP 10month ) The treatment with Mitoxantron was effective :partial regression 5 patients TTP 13 months we have documentated. The effect of the treatment with Imatinib mesylate: stabilization of the dissease 4 patient without mutation TTP longer than 5 months in all cases. Female patient with mutation was treated 8 months only,Sunitinib was ineffective.Patients PDGFR wt are alive more than 2 years with metastatic dissease Conclusions: In our group was PDGFR mutation negative prognostic factor for treatment effect and progression.Patients with ckit wt and PDGFR wt have documentated significantly better prognosis and chemotherapy response.

Citovat

BRANČÍKOVÁ, Dagmar, Markéta PROTIVÁNKOVÁ, Lenka OSTŘÍŽKOVÁ, Zdeněk MECHL and Radek PEJCOCH. Metastatic adeoid cystic carcinoma of the salivary gland. In 2015 ASCO Annual Meeting. 2015. ISSN 0732-183X.

@proceedings{1306357,
   author = {Brančíková, Dagmar and Protivánková, Markéta and Ostřížková, Lenka and Mechl, Zdeněk and Pejcoch, Radek},
   booktitle = {2015 ASCO Annual Meeting},
   keywords = {Adeoid cystic carcinomas},
   language = {eng},
   title = {Metastatic adeoid cystic carcinoma of the salivary gland},
   year = {2015}
}

TY  - CONF
ID  - 1306357
AU  - Brančíková, Dagmar - Protivánková, Markéta - Ostřížková, Lenka - Mechl, Zdeněk - Pejcoch, Radek
PY  - 2015
TI  - Metastatic adeoid cystic carcinoma of the salivary gland
KW  - Adeoid cystic carcinomas
N2  - Background: Adeoid cystic carcinomas of the salivary gland account for approximately 10% of parotid gland tumors. Well-differentiated tumors are characterized by a slow growth rate, a low recurrence rate after complete surgical excision and rare metastatic potential. High-grade tumors are more aggressive, local reccurence rate after surgery approaches 60% and 30% develop distant metastases. We are presenting small group - 6 cases with longer survival after targeted, biological therapy Methods: 6 patients ( 4 males and 2 female) with median age: 50 years. Multiple lung and liver dissemination with all of them. Histology: adenoid cystic carcinoma, KRAS wt, ckit wt, BRAF wt with all. In one women PDGFR mutation on exon 10. No comorbidities, all tumors was clinically symptomatic. Treatment: Combination Cisplatin 50mg/m2 day 1 +Fluorouracil 100mg/m2 48 h continual and docetaxel 60mg/m2 day 1 was used on the first line , after progression in the second line patient was treated with Mitoxantron monotherapy . Third line we indicated imatinib mesylate to patients ckit wt and sunitinib undervent female patient with PDGFR mutation. Results: Therapy using docetaxel and platinum and fluorouracil was effective ( PR 4 patient , median TTP 10month ) The treatment with Mitoxantron was effective :partial regression 5 patients TTP 13 months we have documentated. The effect of the treatment with Imatinib mesylate: stabilization of the dissease 4 patient without mutation TTP longer than 5 months in all cases. Female patient with mutation was treated 8 months only,Sunitinib was ineffective.Patients PDGFR wt are alive more than 2 years with metastatic dissease Conclusions: In our group was PDGFR mutation negative prognostic factor for treatment effect and progression.Patients with ckit wt and PDGFR wt have documentated significantly better prognosis and chemotherapy response.
ER  -

BRANČÍKOVÁ, Dagmar, Markéta PROTIVÁNKOVÁ, Lenka OSTŘÍŽKOVÁ, Zdeněk MECHL and Radek PEJCOCH. Metastatic adeoid cystic carcinoma of the salivary gland. In \textit{2015 ASCO Annual Meeting}. 2015. ISSN~0732-183X.

Detailed Information on Publication Record